참고문헌
- Fasnacht MS, Tolsa JF, Beghetti M; Swiss Society for Pulmonary Arterial Hypertension. The Swiss registry for pulmonary arterial hypertension: the paediatric experience. Swiss Med Wkly 2007;137:510-3.
- Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006. Heart 2009;95:312-7.
- Fraisse A, Jais X, Schleich JM, et al. Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France. Arch Cardiovasc Dis 2010;103:66-74. https://doi.org/10.1016/j.acvd.2009.12.001
- van Loon RL, Roofthooft MT, Hillege HL, et al. Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005. Circulation 2011;124:1755-64. https://doi.org/10.1161/CIRCULATIONAHA.110.969584
- Berger RM, Beghetti M, Humpl T, et al. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet 2012;379:537-46. https://doi.org/10.1016/S0140-6736(11)61621-8
- Barst RJ, McGoon MD, Elliott CG, Foreman AJ, Miller DP, Ivy DD. Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Circulation 2012;125:113-22. https://doi.org/10.1161/CIRCULATIONAHA.111.026591
- Zhou AQ, Zhang QY, DU JB. [Research on pulmonary hypertension in children: present and future]. Zhonghua Er Ke Za Zhi 2011;49:881-5.
- Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(1 Suppl):S55-66. https://doi.org/10.1016/j.jacc.2009.04.011
- Barst RJ, Ertel SI, Beghetti M, Ivy DD. Pulmonary arterial hypertension: a comparison between children and adults. Eur Respir J 2011;37:665-77. https://doi.org/10.1183/09031936.00056110
- Ivy D. Advances in pediatric pulmonary arterial hypertension. Curr Opin Cardiol 2012;27:70-81. https://doi.org/10.1097/HCO.0b013e32835018cd
- Ivy DD, Rosenzweig EB, Lemarié JC, Brand M, Rosenberg D, Barst RJ. Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings. Am J Cardiol 2010;106:1332-8. https://doi.org/10.1016/j.amjcard.2010.06.064
- Fu LJ, Zhou AQ, Guo Y, Zhao PJ, Huang MR, Li F. [Adenosine for pulmonary vasodilator testing in children with idiopathic pulmonary arterial hypertension]. Zhonghua Er Ke Za Zhi 2011;49:886-9.
- Zhang QY, Du JB. Progress on treatment or pulmonary hypertension in children. J Clin Pediatr 2010;28:607-10.
- Tissot C, Ivy DD, Beghetti M. Medical therapy for pediatric pulmonary arterial hypertension. J Pediatr 2010;157:528-32. https://doi.org/10.1016/j.jpeds.2010.06.010
- Yung D, Widlitz AC, Rosenzweig EB, Kerstein D, Maislin G, Barst RJ. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 2004;110:660-5. https://doi.org/10.1161/01.CIR.0000138104.83366.E9
- Simonneau G, Barst RJ, Gaile N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4. https://doi.org/10.1164/ajrccm.165.6.2106079
- Rosenzweig EB, Krishnan U, Takatsuki S, Kerstein J, Calderbank M, Ivy DD. Inhaled treprostinil in pediatric pulmonary arterial hypertension. Am J Respir Crit Care Med 2011;183:A6143.
- Ivy DD, Doran AK, Smith KJ, et al. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol 2008;51:161-9. https://doi.org/10.1016/j.jacc.2007.09.031
- Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin- receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358: 1119-23. https://doi.org/10.1016/S0140-6736(01)06250-X
- Simpson CM, Penny DJ, Cochrane AD, et al. Preliminary experience with bosentan as initial therapy in childhood idiopathic pulmonary arterial hypertension. J Heart Lung Transplant 2006;25:469-73. https://doi.org/10.1016/j.healun.2005.11.438
- Hislop AA, Moledina S, Foster H, Schulze-Neick I, Haworth SG. Longterm efficacy of bosentan in treatment of pulmonary arterial hypertension in children. Eur Respir J 2011;38:70-7. https://doi.org/10.1183/09031936.00053510
- Xu ZM, Zhu LM, Cai XM, Ji G, Liu JF, Su ZK. [Outcome of oral bosentan in children with congenital heart disease associated pulmonary arterial hypertension]. Zhonghua Yi Xue Za Zhi 2009;89:2106-9.
- van Loon RL, Hoendermis ES, Duffels MG, et al. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist? Am Heart J 2007;154:776-82. https://doi.org/10.1016/j.ahj.2007.06.003
- Beghetti M, Hoeper MM, Kiely DG, et al. Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program. Pediatr Res 2008;64:200-4. https://doi.org/10.1203/PDR.0b013e318179954c
- Mourani PM, Sontag MK, Ivy DD, Abman SH. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr 2009;154:379-84, 384.e1-2.
- Barst RJ, Ivy DD, Gaitan G, et al. A randomized, double-blind, placebocontrolled, dose-ranging study of oral sildenafil citrate in treatmentnaive children with pulmonary arterial hypertension. Circulation 2012; 125:324-34. https://doi.org/10.1161/CIRCULATIONAHA.110.016667
- Fox BD, Shimony A, Langleben D. Meta-analysis of monotherapy versus combination therapy for pulmonary arterial hypertension. Am J Cardiol 2011;108:1177-82. https://doi.org/10.1016/j.amjcard.2011.06.021
피인용 문헌
- Bosentan for Treatment of Pediatric Idiopathic Pulmonary Arterial Hypertension: State-of-the-Art vol.7, pp.None, 2012, https://doi.org/10.3389/fped.2019.00302